Takeda Unveils Orexin Findings from Pivotal Oveporexton (TAK-861) Phase 3 Study in Type 1 Narcolepsy at World Sleep 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 08 2025
0mins
Source: Newsfilter
Takeda's Oveporexton Development: Takeda is advancing its investigational oral orexin receptor 2 agonist, oveporexton (TAK-861), for narcolepsy type 1 (NT1), with promising Phase 3 study results showing significant improvements in symptoms and a well-tolerated safety profile.
Clinical Study Outcomes: The Phase 3 studies demonstrated statistically significant enhancements in wakefulness, reduction in cataplexy, and overall quality of life for participants, with over 95% of study completers enrolling in a long-term extension study.
Analyst Views on TAK
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.940
Low
18.00
Averages
18.00
High
18.00
Current: 15.940
Low
18.00
Averages
18.00
High
18.00
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
